ABSTRACT
ObjectiveIn view of the problems of large errors and poor accuracy in pulmonary function testing in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), a predictive classification model of pulmonary function in patients with AECOPD was proposed by comparing the prediction performance of different machine learning models to find the optimal model. MethodsFrom January, 2018 to February, 2020, 90 patients with different degrees of COPD from the Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University were collected. Six machine learning model algorithms (K-nearest neighbor, logistic regression, support vector machine, naive Bayes, decision tree and random forest) were used to establish AECOPD predictive classification models. Their area under the curve of receiver operating characteristic (AUC-ROC) and accuracy were compared. Ten-fold cross-validation method was used to validate the data set. ResultsThe model based on random forest worked best in predicting and classifying AECOPD patients, with an accuracy rate of 0.844 and an AUC-ROC of 0.916. ConclusionRandom forest-based predictive model is a powerful tool for identifying patients with AECOPD, providing decision support when it is difficult to give a definitive diagnosis.
ABSTRACT
Objective:To explore therapeutic effect of rosuvastatin combined clopidogrel bisulfate tablet on patients with coronary heart disease (CHD).Methods: A total of 124 patients, who were diagnosed as CHD by coronary angiography, were selected, randomly and equally divided into routine treatment group (received routine treatment,including clopidogrel bisulfate tablet) and combined treatment group (received rosuvastatin based on routine treatment group), both groups were treated for six months.Cardiac function, serum levels of angiotensin II (Ang II), vascular endothelial growth factor (VEGF) and nitric oxide (NO), and therapeutic effect were measured and compared between two groups before and after treatment.Results: Total effective rate of combined treatment group was significantly higher than that of routine treatment group (96.77% vs.83.87%, P=0.015).Compared with routine treatment group after treatment, there were significant rise in left ventricular ejection fraction [(61.89±7.02)% vs.(68.96±8.23)%] and NO level [(75.25±9.45) μmol/L vs.(82.25±10.22) μmol/L], and significant reductions in wall motion score index [(1.35±0.39)% vs.(1.11±0.29)%], levels of Ang Ⅱ [(102.25±6.93) ng/L vs.(52.99±5.36) ng/L] and VEGF [(328.25±23.41) ng/L vs.(228.69±22.69) ng/L] in combined treatment group, P<0.01 all.Conclusion: Rosuvastatin combined clopidogrel bisulfate tablet can effectively improve heart function, serum levels of Ang II, VEGF and NO in patients with coronary heart disease, the therapeutic effect is significant, which is worth extending.